Drugs firms profiteer from NHS by hiking cancer drugs prices
Drug companies are profiteering from the NHS to the tune of 1 billion because they have unjustifiably hiked prices of cancer medicine, experts warn. Cancer patients are let down by greedy drug companies who delay availability of well-established treatments and raise the prices beyond what the NHS can afford, academics said.